1. Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases
   Shizuya Yamashita et al, 2020, Current Atherosclerosis Reports CrossRef
2. Fibroblast growth factor 21 potentially inhibits microRNA-33 expression to affect macrophage actions
   Yuan Guo et al, 2016, Lipids in Health and Disease CrossRef
3. Endocytosis of LXRs: Signaling in liver and disease
   Mettle Brahma et al, 2023, Receptor Endocytosis and Signalling in Health and Disease - Part A CrossRef
4. Anti-oxidant response of lipidom modulates lipid metabolism in Caenorhabditis elegans and in OxLDL-induced human macrophages by tuning inflammatory mediators
   Acharya Balkrishna et al, 2023, Biomedicine & Pharmacotherapy CrossRef
5. Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases
   Shizuya Yamashita et al, 2019, Journal of Atherosclerosis and Thrombosis CrossRef
6. Vascular protection with fibroblast growth factor 21 in diabetes: Its potential beyond glucose and lipid control
   Mi-Hua Liu, 2015, International Journal of Cardiology CrossRef
7. Apolipoprotein E deficiency and high-fat diet cooperate to trigger lipidosis and inflammation in the lung via the toll-like receptor 4 pathway
   QIUFANG OUYANG et al, 2015, Molecular Medicine Reports CrossRef
8. Recombinant Klotho protein enhances cholesterol efflux of THP-1 macrophage-derived foam cells via suppressing Wnt/β-catenin signaling pathway
   Wei Liu et al, 2020, BMC Cardiovascular Disorders CrossRef
9. Overexpression of β-Klotho in Adipose Tissue Sensitizes Male Mice to Endogenous FGF21 and Provides Protection From Diet-Induced Obesity
   Ricardo J. Samms et al, 2016, Endocrinology CrossRef
10. The role of oxidation of low-density lipids in pathogenesis of osteoarthritis: A narrative review
    Kazuhiko Hashimoto et al, 2020, Journal of International Medical Research CrossRef
11. Analysis of Low Molecular Weight Substances and Related Processes Influencing Cellular Cholesterol Efflux
    Dmitry Y. Litvinov et al, 2019, Pharmaceutical Medicine CrossRef
12. Mechanisms of antidiabetic drugs and cholesterol efflux: A clinical perspective
    Ali Ahmadi et al, 2022, Drug Discovery Today CrossRef
13. Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis
    Shizuya Yamashita et al, 2023, Metabolites CrossRef
14. Fibroblast growth factor 21 regulates foam cells formation and inflammatory response in Ox-LDL-induced THP-1 macrophages
    Nan Wang et al, 2018, Biomedicine & Pharmacotherapy CrossRef
15. Inhibition of the ox-LDL-Induced Pyroptosis by FGF21 of Human Umbilical Vein Endothelial Cells Through the TET2-UQCRC1-ROS Pathway
    Jiao-Jiao Chen et al, 2020, DNA and Cell Biology CrossRef
16. New Strategies to Promote Macrophage Cholesterol Efflux
    Hong Y. Choi et al, 2021, Frontiers in Cardiovascular Medicine CrossRef
17. Regulation of longevity by FGF21: Interaction between energy metabolism and stress responses
    Antero Salminen et al, 2017, Ageing Research Reviews CrossRef
18. Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia
    Shizuya Yamashita et al, 2018, Journal of Clinical Lipidology CrossRef
19. Adipokines in atherosclerosis: unraveling complex roles
    Jiaying Luo et al, 2023, Frontiers in Cardiovascular Medicine CrossRef
20. Implication of hepatokines in metabolic disorders and cardiovascular diseases
    Tae Woo Jung et al, 2016, BBA Clinical CrossRef
21. The roles of FGF21 in atherosclerosis pathogenesis
    Farzane Shanebandpour Tabari et al, 2019, Reviews in Endocrine and Metabolic Disorders CrossRef
22. Adipokines, adiposity, and atherosclerosis
    Longhua Liu et al, 2022, Cellular and Molecular Life Sciences CrossRef
23. Metabolic Inflammation—A Role for Hepatic Inflammatory Pathways as Drivers of Comorbidities in Nonalcoholic Fatty Liver Disease?
    Nadine Gehrke et al, 2020, Gastroenterology CrossRef
24. Metformin promotes cholesterol efflux in macrophages by up-regulating FGF21 expression: a novel anti-atherosclerotic mechanism
    Fei Luo et al, 2016, Lipids in Health and Disease CrossRef
25. Fibroblast growth factor 21 in chronic kidney disease
    Paulo Giovanni de Albuquerque Suassuna et al, 2019, Journal of Nephrology CrossRef